MARKET

DVAX

DVAX

Dynavax Techs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.560
-0.030
-0.84%
After Hours: 3.800 +0.24 +6.74% 17:26 03/27 EDT
OPEN
3.620
PREV CLOSE
3.590
HIGH
3.920
LOW
3.540
VOLUME
1.61M
TURNOVER
--
52 WEEK HIGH
8.19
52 WEEK LOW
1.800
MARKET CAP
306.83M
P/E (TTM)
-1.6147
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of DVAX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average DVAX stock price target is 13.67 with a high estimate of 20.00 and a low estimate of 9.00.

EPS

DVAX News

More
  • Dynavax's stock rises 10% on expanded CEPI partnership
  • MarketWatch · 3d ago
  • Dynavax +19% premarket on coronavirus vaccine deal with CEPI
  • seekingalpha · 3d ago
  • 3 Biotech Stocks to Watch as the Race for a Coronavirus Vaccine Continues
  • TipRanks · 3d ago
  • Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)
  • GlobeNewswire · 3d ago

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About DVAX

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.
More

Webull offers kinds of Dynavax Technologies Corporation stock information, including NASDAQ:DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions.